Viewing Study NCT02238834

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:37 AM
Ignite Modification Date: 2026-02-27 @ 5:10 PM
Study NCT ID: NCT02238834
Status: COMPLETED
Last Update Posted: 2022-08-08
First Post: 2014-09-05
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Phase 1 Safety, Tolerability and Pharmacokinetics (PK) Study of FP-025 in Healthy Volunteers
Sponsor: Foresee Pharmaceuticals Co., Ltd.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Healthy View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Phase I View
None Safety and tolerability View
None Pharmacokinetic View
None Randomized View
None Double Blind View
None Placebo-Controlled View
None Single- & Multiple Dose Escalation View
None FP-025 View
None MMP-12 inhibitor View